What is RVTY's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for RVTY.

Stock Ratings / Health Care / RVTY / options

AVTR (56) BIO (62) MTD (78) TXG (59) ⌘ Pro Terminal →

Revvity Inc. (RVTY) Options Positioning, Max Pain & Unusual Sweeps

$151.60 -3.44% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $150.37

Revvity Inc. (RVTY) carries a Roarable Rating of C (Hold) with 65/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $17.52B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RVTY Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RVTY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Revvity Inc. (NYSE: RVTY) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $151.60 (-3.44% 1D, market cap $17.52B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 9/20. Across 1016 tracked Health Care issuers, RVTY ranks #115 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RVTY compare to AVTR and BIO in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), RVTY carries a Roarable C (65/100 RQD), trailing P/E of 76.7x, gross margin of —, and ROIC of 3.1%. By comparison, AVTR (Avantor Inc.) holds a D+ grade (56/100 RQD, P/E N/A, ROIC -2.1%, cap $10.88B) and BIO (Bio-Rad Laboratories Inc.) posts a C grade (62/100 RQD, P/E 13.5x, ROIC 0.5%, cap $9.95B). Among the 5-stock peer group, BIO leads on earnings multiple (13.5x) while MTD leads on capital efficiency (30.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RVTY?

▼

Per RVTY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-28, CIK 0000031791), Revvity Inc. generated $2.86B in revenue (+3.7% YoY), $241.2M in net income, and $509.4M in free cash flow against $12.17B in total assets and $2.63B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $150.37 (-0.81%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 17.8% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 65/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.3% avg 90D alpha vs SPY • 55.6% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+3.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RVTY)Realized 20D OHLCV Swing Band: ±7.2%

Deterministic 5-Pillar Attribution (65/100 Composite)

🔍 WHY RVTY SCORES 65/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (25% of score)

20D Institutional Volume Accumulation (±7.2% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (25% of score)

Altman Z-Score 3.37 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B$152.12+3% Next Q

Q2 (-2Q)

Grade B$156.61+5.6% Next Q

Q3 (-1Q)

Grade B-$165.33-8.3% Next Q

Current

Grade C$151.60+1.3% Hist 90D α

Trajectory: B (73) → C (65)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the RVTY Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 65/100 (C) score, RVTY faces multiple-compression risk if 76.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Priced at 77x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($146.80) or 200D SMA ($112.63) invalidates the momentum regime and cuts Target Base ($156.38) toward Bear Floor ($121.98).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RVTY• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RVTY Beats Next Quarter EPS Consensus (Dec 27, 2026) & Holds Above 200D SMA”

YES 65%NO 35%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±7.2%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (RVTY)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for RVTY.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating RVTY & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on RVTY
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RVTY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +75.24%▲ ASCENDING CHANNEL

2026-11-03O $165.8H $165.8L $151.6C $151.6VOL 3.18M

RES: $180.7SUP: $141.0SMA50: $146.8SMA200: $112.6

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RVTY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RVTY Butterfly Map → + Track RVTY →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

48.0%/yr Implied 5Y Growth

vs. +3.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on RVTY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RVTY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RVTY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RVTY)

Health Care Rank #115 of 1016 ⚔️ AVTR vs RVTY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RVTY vs. AVTR, BIO, MTD, TXG)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Revvity Inc. (RVTY) ranks #115 by composite RQD confidence (65/100, grade C) and #74 by equity capitalization ($17.52B). Within this direct 5-issuer industry benchmark cohort, BIO leads on earnings valuation at 13.5x trailing P/E, while MTD leads on capital efficiency and profitability with 30.4% ROIC and 59.4% gross margin. MTD currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with RVTY at 65/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RVTY ACTIVE Revvity Inc.	C	65/100	76.7x	—	3.1%	-3.44%	$17.52B	Benchmark Subject
AVTR Avantor Inc.	D+	56/100	—	32.7%	-2.1%	-2.74%	$10.88B	/avtr-vs-rvty →
BIO Bio-Rad Laboratories Inc.	C	62/100	13.5x	51.9%	0.5%	-1.62%	$9.95B	/bio-vs-rvty →
MTD Mettler-Toledo International Inc.	B+	78/100	39.6x	59.4%	30.4%	+0.20%	$33.56B	/mtd-vs-rvty →
TXG 10x Genomics Inc.	C-	59/100	—	69.1%	-5.7%	-12.09%	$9.13B	/txg-vs-rvty →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-28 • CIK 0000031791 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-28), Revvity Inc. (RVTY) reported GAAP revenue of $2.86B (+3.7% vs. FY2024 revenue of $2.76B , and +3.8% cumulative change since FY2023) , GAAP net income of $241.2M, operating cash flow of $582.9M, and free cash flow of $509.4M (-6.0% YoY). On the balance sheet, RVTY closed FY2025 with $12.17B in total assets against $2.63B in total debt (Altman Z-Score: 3.37, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-28	$2.86B	$241.2M	$582.9M	$509.4M	$12.17B	$2.63B
FY2024 (FY)	2024-12-29	$2.76B	$270.4M	$628.3M	$541.7M	$12.39B	$3.15B
FY2023 (FY)	2023-12-31	$2.75B	$693.1M	$91.3M	-$32.5M	$10.17B	$2.38B

3. RVTY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RVTY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does RVTY compare to AVTR and BIO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for RVTY?

Where is RVTY trading relative to its 50-day, 200-day, and 52-week technical levels?

RVTY last traded at $151.60 (-3.44% on volume of 2,798,703 shares), positioning the stock +3.27% above its 50-day simple moving average ($146.80) and +34.60% above its 200-day simple moving average ($112.63). Across its 52-week range of $81.22 to $169.06, RVTY sits at the 80.1% percentile with a 14-day RSI of 51.9 (NEUTRAL RANGE) and an implied next-earnings move of ±7.2% ($140.68 to $162.52).

Direct Sub-Reports: RVTY RQD Cockpit RVTY 12M Forecast RVTY Earnings & Move RVTY Dividends & DRIP RVTY Insiders & 13F RVTY Whale Options RVTY Profit Sankey RVTY News & Why

ROARABLE RATING BRIEF • RQD 65/100 (C) ✓ SEC XBRL & RQD VERIFIED

RVTY — Revvity Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-28

1. Roarable Rating Brief: What This Means to a Prospective Investor

Revvity Inc. (RVTY) earns a live Roarable RQD composite score of 65/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $151.60 (-3.44% 1D, market capitalization $17.52B).

Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of 3.1%, gross margin of —, operating margin of 12.5%, and free cash flow yield of 2.75%.
Whale 13F & Options Flow (16/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (12/20) + Forensic Balance Sheet (16/20): Incorporates a 0.95x equity beta, Altman Z-Score of 3.37, Piotroski F-Score of 7/9, and Debt/Equity of 0.36x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Revvity Inc. (RVTY) is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Laboratory Analytical Instruments industry..5B. — for further business detail.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-28), Revvity Inc. (RVTY) reported $2.86B in annual revenue (up from $2.76B in FY2024, +3.7% YoY) and $241.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.75B revenue, $693.1M net income) through FY2025, RVTY scaled operating cash flow to $582.9M and free cash flow to $509.4M, backed by $12.17B in total assets against $2.63B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (C • RQD 65/100): Big institutional funds and options desks are actively positioning on the bullish side. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $81.22 – $169.06 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 76.7x trailing P/E and 48.2x EV/EBITDA against 12.5% operating margins and a 0.95x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the provided material.

Key Question #1: Can RVTY sustain or expand its 12.5% operating margin and 3.1% ROIC against Biotechnology: Laboratory Analytical Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $2.86B and free cash flow of $509.4M, how will capital allocation balance growth reinvestment against $2.63B in total debt?
Key Question #3: How sensitive is RVTY's 71.3x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.95x)?

RVTY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Revvity Inc. (RVTY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RVTY Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 21h ago

Revvity (RVTY) Stock Could Be 12% Stretched On Cash Flow

Yahoo Finance report covering Revvity Inc. (RVTY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stocktwits • 1d ago

RVTY: Revvity Inc. Latest Stock Price, Analysis, News and Trading Ideas

Stocktwits report covering Revvity Inc. (RVTY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Trefis • 1d ago

A 7-Day Winning Streak Has Revvity Stock Up 9.6%

Trefis report covering Revvity Inc. (RVTY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Revvity (RVTY), What Is Drawing Fresh Attention Now?

Yahoo Finance report covering Revvity Inc. (RVTY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Revvity: High PEG Ratio Leaves Limited Near-Term Upside (NYSE:RVTY)

Seeking Alpha report covering Revvity Inc. (RVTY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

What's Going On With Revvity Stock Tuesday? - Revvity (NYSE:RVTY)

Benzinga report covering Revvity Inc. (RVTY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Revvity Gears Up to Post Q3 Earnings: What's in Store for the Stock?

TradingView report covering Revvity Inc. (RVTY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Revvity (RVTY) Stock May Be Trading At A Premium On Its AI Workflow Launch

Yahoo Finance report covering Revvity Inc. (RVTY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RVTY Bull vs. Bear Conversation Board — What's Your Call at $151.60?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RVTY 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $189.97 (+21.0%)

📌 Pinned Debate

Institutional whale flow scores 19/20 and the forensic balance sheet scores 16/20, with Altman Z at 3.37 and Piotroski F at 7/9.

Institutional whale flow scores 19/20 and the forensic balance sheet scores 16/20, with Altman Z at 3.37 and Piotroski F at 7/9.. When you look under the hood at RVTY, Fundamental Cash Engine is 12/20 with 0.0% gross margins and 3.1% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (16/20) has been quietly accumulating below $169.06. My 12M target is $189.97.

SectorRotator 🐂 BULL

@SiliconVal_Bull Agree on the RQD 65/100 quality, though with 0.95 beta I'm scaling in with half-size at $157.00 and keeping dry powder in case we test $146.01.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $125.60 (-20.0%)

Spot @ $157.00

Trailing P/E of 76.7 and EV/EBITDA of 48.2 sit against a 3.1% ROIC and 2.75% FCF yield, with insider conviction scoring only 9/20.

Trailing P/E of 76.7 and EV/EBITDA of 48.2 sit against a 3.1% ROIC and 2.75% FCF yield, with insider conviction scoring only 9/20.. Look at the math on RVTY: paying 76.7x trailing P/E for 3.1% ROIC and 12.5% operating margins leaves zero margin of safety if Biotechnology: Laboratory Analytical Instruments demand softens. I'd wait for a retest of $138.16 before getting long.